HDAC-IN-93 

HDAC-IN-93 is a HDAC inhibitor with promising total pan-HDAC inhibitory activity. HDAC-IN-93 demonstrates significant broad-spectrum antiproliferative activity across various cancer cell lines. HDAC-IN-93 induces cell apoptosis along with necrosis. HDAC-IN-93 can be used for the studies of prostate cancer and breast cancer^[1].

HDAC-IN-93 (Compound 17) is sensitive to a variety of cancer cell lines, with particularly significant effects on prostate cancer PC-3 cells and breast cancer MCF-7 cells with IC₅₀ values of 4.1 μM and 20.8 μM, respectively^[1].
HDAC-IN-93 (4.1 μM, 24 h) causes a significant increase in the number of cells in the SubG0-G1 phase, and induces early apoptosis in MCF-7 cells^[1].
HDAC-IN-93 (4.1 μM, 24 h) upregulates pro-apoptotic genes (Bax, Cyt-C, Caspase-3) and downregulates anti-apoptotic genes (Bcl-2) in MCF-7 cells^[1].
HDAC-IN-93 (4.1 μM, 24 h) shows total HDAC inhibitory activity of 66.1 % at MCF-7 although shows relatively weak direct inhibitory activity against specific HDAC subtypes (6, 7, 8)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

306.32

C₁₈H₁₄N₂O₃

N/C(C(C=C1)=CC=C1/C=C/C2=CC(C3=CC=CC=C3O2)=O)=N\O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ashraf R, et al. Design and synthesis of novel Hydroxamate and non-Hydroxamate HDAC inhibitors based on Chromone and Quinazolone scaffolds. Bioorg Chem. 2025 Jul 1;161:108514.  [Content Brief]